Global Endometriosis Treatment Market-Trends, Top Manufactures, Market Demands, Industry Growth Forecast: 2025

The latest report on Endometriosis Treatment Market by Infinium Global Research gives complete coverage of the endometriosis treatment market by drug type (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDS), treatment type (hormonal therapy, and pain management), distribution channel (hospital, pharmacies, retail pharmacies, and e-commerce.) in terms of key trends, market size, forecast. In addition, the study covers deep dive into key product and applications trends in the regional markets of endometriosis treatment such as North America, Europe, Asia-Pacific and Latin America over the short run and long run. The global endometriosis treatment market is projected to grow at a CAGR of 2.8% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Research [email protected]

Endometriosis Treatment Market: Industry Insights

Endometriosis affects between 6 to 10 percent of women of reproductive age worldwide. It occurs when endometrial implants, comprised of tissue normally found within the uterus, are present in other areas of the body. The medical and surgical treatments for endometriosis help to decrease symptoms and discomfort. Initial therapies include nonsteroidal anti-inflammatory drugs and hormonal contraceptives. FDA approved gonadotropin-releasing hormone (GnRH) agonists and Elagolix are used as a second line treatment for endometriosis.

Endometriosis Treatment Market: Drivers and Restraints

The growing prevalence of endometriosis and increasing awareness about this medical condition is driving the growth of the endometriosis treatment market. Endometriosis affects an estimated 1 in 10 women during their reproductive years usually between the ages of 15 to 49, which is approximately 176 million women in the world. Endometriosis is a condition which leads to infertility. Therefore, the rising demand for treatment is also due to rising awareness about infertility. However, the lack of non-invasive diagnostic tests and low awareness about endometriosis in certain regions hampers the growth of the endometriosis treatment market. Moreover, the growing research and development in the drug development of endometriosis are anticipated to provide opportunities for the endometriosis treatment market.

Enquire here Get Customization & Check Discount for Report @

Endometriosis Treatment Market: Segmentation

The global endometriosis market is segmented into drug type, treatment type, and distribution channel. The drug types include oral contraceptives, progestins, NSAIDs, GnRH Analogues, LNR-IUDs, and others. Among them, GnRH analogs hold a dominant share among the drug types as they are most commonly prescribed as a second-line treatment option for the endometriosis condition. The treatment types include hormonal therapy and pain management. The pain management segment holds the largest share among the treatment type as pain management therapy is the primary therapy that is initially recommended for treating severe pain due to endometriosis. The distribution channels include hospital pharmacies, retail pharmacies, and e-commerce.

Endometriosis Treatment Market: Regional Insights

North America holds the dominant share in the global endometriosis treatment market. The growing prevalence of endometriosis is primarily contributing to the growth of the market. Additionally, it is estimated that between 10 percent and 20 percent of American women of childbearing age have endometriosis. Furthermore, better awareness about endometriosis, established medical infrastructure, high spending capacity on healthcare needs and easy availability of drugs for the treatment of endometriosis fuels the growth of the endometriosis treatment market.

Browse Detailed TOC and Description of this Exclusive [email protected]

Endometriosis Treatment Market: Competitive Landscape

The major market players that are involved in the endometriosis treatment market are Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., Bayer AG, AbbVie Inc., Meditrina Pharmaceuticals Private Limited, Pfizer Inc., Neurocrine Biosciences Inc., and Takeda Pharmaceutical Company. The major manufacturers are focusing on the development of new products and several products are under FDA review. In July 2018, AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis. About 1 in 10 women suffer from endometriosis during their reproductive years, so approval of Elagolix, a short-acting, oral, nonpeptide, GnRH antagonist, is anticipated to accelerate the annual sales of the company.

Reasons to Buy this Report:

  • Comprehensive analysis of global as well as regional markets of the endometriosis treatment.
  • Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
  • Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  
  • Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Related Articles